Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20

LESSONS LEARNED. There continues to be a lack of systemic options for advanced hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only approved options. There exists a potential to combine sorafenib with chemotherapeutic agents shown to be active in HCC, such as capeci...

Descripción completa

Detalles Bibliográficos
Autores principales: Patt, Yehuda, Rojas‐Hernandez, Cristhiam, Fekrazad, Houman Mohammad, Bansal, Pranshu, Lee, Fa Chyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634773/
https://www.ncbi.nlm.nih.gov/pubmed/28687627
http://dx.doi.org/10.1634/theoncologist.2017-0168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634773/
https://www.ncbi.nlm.nih.gov/pubmed/28687627
http://dx.doi.org/10.1634/theoncologist.2017-0168

Ejemplares similares